(A) DU-145 cells were treated with IL-4 to induce STAT6 protein phosphorylation with and without coadministration of cisplatin (10, 5 or 2.5 μg/ml) for 18 hours; maximum concentration found in blood is approx. 5 μg/ml. STAT6 expression and phosphorylation was analyzed by western blot. Shown is one representative experiment out of 2 independent experiments. (B) DU-145 or BLM cells were treated with IL-6/IFNγ to induce STAT1 and STAT3 phosphorylation or IL-4 to induce STAT6 phosphorylation with and without co-administration of cisplatin (10 μg/ml), oxaliplatin (25 or 14 μg/ml), or carboplatin (120 or 80 μg/ml) for 18 hours. Tubulin (pSTAT1 and pSTAT3) or Actin (pSTAT6) is shown as a loading control. Shown are two independent experiments.
Supplementary Figure 2: (A)
Recombinant STAT protein is biotynilated and pTyr peptide is coupled to FITC. pTyr binds to the STAT SH2 domain. Streptavidin-coupled donor beads and anti-FITC antibody-coupled acceptor beads are added to the mix. Binding of pTyr to STAT SH2 domain brings donor-and acceptor beads in close proximity, thereby allowing energy transfer via singlet oxygen molecules leading to fluorescence emission by the acceptor beads. (B) Hypothesis: cisplatin binds to and blocks the STAT SH2 domain thus inhibiting pTyr binding and no energy is transferred to the acceptor beads. (C) A non-labeled pTyr peptide was added to the assay as a competitor. (D) Biotin donor beads were incubated with streptadivin-coupled acceptor beads in the presence of cisplatin and the fluorescence was measured. (E) Cisplatin was added to donor bead-coupled STAT3 15 min before or at the same time as addition of acceptor bead-coupled pTyr peptide. Emission was measured 90 minutes after addition of pTyr. For the after samples: STAT3 was incubated with pTyr for 90 minutes and cisplatin was added before measurement of emission.
